tbuckley/cabot-search huggingface dataset:
Prognostic Factors and Treatment Outcome in Lymphocyte Predominant and Classical Hodgkin’s Lymphoma: A Comprehensive Analysis of the German Hodgkin Study Group.
Authors: Lucia Nogova, Thorsten Reineke, Corinne Brillant, Thomas Ruediger, Hans K. Mueller-Hermelink, Henning Bredenfeld, Andreas Josting, Rolf P. Mueller, Volker Diehl, Andreas Engert
Journal: Blood (2006)
P1.03-38 EGFR Mutation Status as a Prognostic Marker in Stage 1 Lung Adenocarcinoma After Definitive Surgical Resection
Authors: C. Galvez, S. Jacob, J. Zhao, K. Tegtmeyer, B. Finkelman, Y.K. Chae, N. Mohindra, B. Jovanovic, A. Behdad, V. Villaflor
Journal: Journal of Thoracic Oncology (2019)
Abstract 13241: On-Treatment Progression of Cornell Voltage is Associated With Adverse Cardiovascular Outcomes in Patients With Diabetes
Authors: Radmila Lyubarova, Jackie Szymonifka, Joshua Schulman-Marcus, Bríain Ó Hartaigh, Elsayed Z Soliman, Peter M Okin
Journal: Circulation (2018)

Introduction: Regression of ECG left ventricular hypertrophy (LVH) with blood pressure (BP) lowering therapy is associated with reduced cardiovascular (CV) events. It is unknown whether this associ...
P2.01-81 Predictive Factors of Survival in Patients Treated with Nintedanib: A Multicenter Retrospective Spanish Study
Authors: P. Cruz, L. Gutiérrez Sainz, M. Antoñanzas, C. Aguado, X. Mielgo, L. Cabezón, L.E. Chara, E. Martinez Moreno, Y. Lage Alfranca, A. Velastegui, M. Sotelo, A. Garcia Rueda, M.E. Olmedo, S. Martínez Recio, J. De Castro Carpeno
Journal: Journal of Thoracic Oncology (2019)
MA10.05 Breath Analysis: New Key-Challenges for Early Detection of Lung and Pleural Neoplasms
Authors: A. Catino, G. De Gennaro, A. Di Gilio, L. Facchini, D. Galetta, T. Mongelli, J. Palmisani, F. Porcelli, N. Varesano, P. Pizzutilo, M. Montrone, V. Longo, G. Del Bene, A. Mastrandrea, F. Pesola, D. Ricci, P. Petrillo, A. Zacheo
Journal: Journal of Thoracic Oncology (2019)
Effect of thermomechanical treatment on the mechanical and microstructural evolution of a β-type Ti-40.7Zr–24.8Nb alloy
Authors: Sertan Ozan, Jixing Lin, Weijie Weng, Yaowu Zhang, Yuncang Li, Cuie Wen
Journal: Bioactive Materials (2019)

In this study, the microstructural evolution and mechanical properties of a newly developed Ti-40.7Zr-24.8Nb (TZN) alloy after different thermomechanical processes were examined. As-cast TZN alloy plates were solution-treated at 890 °C for 1 h, after which the thickness of the alloy plates was reduced by cold rolling at reduction ratios of 20%, 56%, 76%, and 86%. Stress-induced α" formation, {332} <113> β mechanical twinning, and kink band formation were observed in the cold-rolled TZN alloy samples. In the TZN sample after cold rolling at the 86% reduction ratio plus a recrystallization annealing at 890 °C for 1 h, the deformation products of a stress-induced α" phase, {332}<113> β mechanical twinning, and kink bands disappeared, resulting in a fine, equiaxed single β phase. The alloy samples exhibited elongation at rupture ranging from 7% to 20%, Young's modulus ranging from 63 to 72 GPa and tensile strength ranging from 753 to 1158 MPa. The TZN alloy sample after cold rolling and recrystallization annealing showed a yield strength of 803 MPa, a tensile strength of 848 MPa, an elongation at rupture of 20%, and an elastic admissible strain of 1.22%, along with the most ductile fractures during tensile testing.
The geography of ASCO Annual Meetings: Nationality of abstracts and recent trends
Authors: E. D. Saad, A. Mangabeira, A. L. Masson, F. E. Prisco
Journal: Journal of Clinical Oncology (2009)

e17567 Background: Although there have been previous analyses of various aspects of studies presented at ASCO Annual Meetings, to our knowledge no attempt has been made to investigate the nationality of abstracts. Methods: After stratification into three categories of presentation ([1] oral, including plenary and all oral presentations; [2] posters, including poster discussions; and [3] publication only [PO]), we took a random sample of 10% of the abstracts from 6 years, and assigned them nationalities using authors’ affiliations. For multinational studies, we assigned nationality following an algorithm developed for the study. Importantly, we did not appraise abstract quality or results. Results: We analyzed 2,206 of the 22,045 abstracts appearing in the Proceedings and LBA Booklets for 2001–2003 and 2006–2008. Categories were oral/poster/PO in 7.8/49.2/43.0%, and study phase (as declared by authors) was I/II/III/other, unknown or not applicable in 10.8/16.5/3.3/69.4% of abstracts. There were 332 (15.0%) multinational studies, and 1,866 (85.0%) were uninational (969 multicenter, and 905 from a single institution). The top 15 countries with higher % of studies were the US (49.0%), Italy (7.5%), Japan (5.9%), Germany (5.3%), France (4.3%), Spain (3.5%), Canada (3.4%), the UK (3.3%), South Korea (1.8%), China/Hong Kong (1.4%), Brazil (1.1%), India (1.0%), Greece and Belgium (0.9% each), and Turkey (0.8%). Exploratory analyses showed a temporal increase in multinational studies (p = 0.003), no temporal trend in the proportion of abstracts with US nationality (p = 0.315), and a higher proportion of oral and poster presentations for multinational studies (p &lt; 0.001) and for abstracts with US nationality (p &lt; 0.001). Conclusions: This bibliometric analysis provides a geographic overview of research presented at ASCO Annual Meetings and suggests that nearly half of all abstracts are from the US, with 20% of the 71 countries represented producing nearly 90% of all abstracts accepted for the meetings. Multinational collaboration seems to be increasing in clinical cancer research. No significant financial relationships to disclose.
Clonality, Antigen Recognition, and Suppression of CD8+ T Cells Differentially Affect Prognosis of Breast Cancer Subtypes
Authors: Dora Hammerl, Maarten P.G. Massink, Marcel Smid, Carolien H.M. van Deurzen, Hanne E.J. Meijers-Heijboer, Quinten Waisfisz, Reno Debets, John W.M. Martens
Journal: Clinical Cancer Research (2019)

Abstract Purpose: In breast cancer, response rates to immune therapies are generally low and differ significantly across molecular subtypes, urging a better understanding of immunogenicity and immune evasion. Experimental Design: We interrogated large gene-expression data sets including 867 node-negative, treatment-naïve breast cancer patients (microarray data) and 347 breast cancer patients (whole-genome sequencing and transcriptome data) according to parameters of T cells as well as immune microenvironment in relation to patient survival. Results: We developed a 109–immune gene signature that captures abundance of CD8 tumor-infiltrating lymphocytes (TIL) and is prognostic in basal-like, her2, and luminal B breast cancer, but not in luminal A or normal-like breast cancer. Basal-like and her2 are characterized by highest CD8 TIL abundance, highest T-cell clonality, highest frequencies of memory T cells, and highest antigenicity, yet only the former shows highest expression level of immune and metabolic checkpoints and highest frequency of myeloid suppressor cells. Also, luminal B shows a high antigenicity and T-cell clonality, yet a low abundance of CD8 TILs. In contrast, luminal A and normal-like both show a low antigenicity, and notably, a low and high abundance of CD8 TILs, respectively, which associates with T-cell influx parameters, such as expression of adhesion molecules. Conclusions: Collectively, our data argue that not only CD8 T-cell presence itself, but rather T-cell clonality, T-cell subset distribution, coinhibition, and antigen presentation reflect occurrence of a CD8 T-cell response in breast cancer subtypes, which have been aborted by distinct T-cell–suppressive mechanisms, providing a rationale for subtype-specific combination immune therapies.
CpG island promoter hypermethylation of the BRCA1-binding protein SRBC occurs in the context of a wild-type BRCA1 in breast cancer
Authors: Amaia Lujambio, Mario F. Fraga, Manel Esteller
Journal: Cancer Research (2006)

1609  Imbalance of the BRCA1 pathway is a major hallmark of human breast cancer. In this context, germline point mutation and CpG island promoter hypermethylation of BRCA1 are a feature of breast neoplasms. Inactivation by promoter hypermethylation of the BRCA1-binding protein SRBC could constitute another way by which this cellular network may be altered in human cancers. If both BRCA1 and SRBC act in the same pathway, simultaneous molecular lesions in the two genes in the same tumor should be a rare event. To test whether this inverse association exists, we have analyzed the BRCA1 and BRCA2 mutational and CpG island hypermethylation status versus SRBC CpG island hypermethylation of a large collection of sporadic and inherited breast tumors. No association was found between the methylation status of SRBC and the BRCA2 mutational status. However, our results demonstrate that the epigenetic alteration of SRBC is confined to breast tumors without BRCA1 hypermethylation or BRCA1 germline mutations. Thus, the mutual exclusivity of the epigenetic and genetic alterations in BRCA1 and SRBC suggests that both genes play a critical and cooperative role in human tumorigenesis.
P2.15-09 Clinical Features and Prognosis of Primary Tracheal Cancer at Our Institution’s Experience
Authors: Y. Mishina, H. Arai, S. Nakamura, H. Masuda, K. Shiino, K. Okudela, T. Iwasawa, M. Tajiri, M. Masuda
Journal: Journal of Thoracic Oncology (2019)
P1.12-17 Association Between the Pharmacokinetics and Clinical Outcome of Amrubicin Treatment
Authors: S. Fukuda, T. Oguri, O. Takakuwa, Y. Kagawa, A. Takeuchi, K. Sone, K. Fukumitsu, Y. Kanemitsu, T. Uemura, H. Ohkubo, M. Takemura, K. Maeno, Y. Ito, A. Niimi
Journal: Journal of Thoracic Oncology (2019)
Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin
Authors: Thomas A Pollak, Belinda R Lennox, Sabine Müller, Michael E Benros, Harald Prüss, Ludger Tebartz van Elst, Hans Klein, Johann Steiner, Thomas Frodl, Bernhard Bogerts, Li Tian, Laurent Groc, Alkomiet Hasan, Bernhard T Baune, Dominique Endres, Ebrahim Haroon, Robert Yolken, Francesco Benedetti, Angelos Halaris, Jeffrey H Meyer, Hans Stassen, Marion Leboyer, Dietmar Fuchs, Markus Otto, David A Brown, Angela Vincent, Souhel Najjar, Karl Bechter
Journal: The Lancet Psychiatry (2019)
JCSE01.26 PD-1 Inhibitor Plus Chemotherapy as 2nd/Subsequent Line Setting Demonstrate Superior Efficacy over PD-1 Inhibitor Alone in Pts of Advanced NSCLC
Authors: S. Ren, Y. Liu, F. Zhou, T. Jiang, C. Su, X. Chen, C. Zhou
Journal: Journal of Thoracic Oncology (2019)
P2.01-06 Phase I Study of Nivolumab and Ipilimumab Combined with Nintedanib in Advanced Non-Small Cell Lung Cancer
Authors: S. Puri, N. Rodriguez Guadalupe, S. Niyongere, T. Boyle, R. Thapa, D. Chen, D. Noyes, M. Chatwal, S. Antonia, J.E. Gray
Journal: Journal of Thoracic Oncology (2019)
Urgent and emergency care: most people report good care, but lengthy waits are a problem, survey finds
Authors: Abi Rimmer
Journal: BMJ (2019)

The Care Quality Commission has published the results of a survey of patients who had urgent and emergency care from services provided by 132 NHS trusts across England during September 2018. Of the respondents, 42 707 visited an emergency department and 7419 visited an urgent care centre, urgent treatment centre, or minor injury unit.

Most people (75%) who attended an emergency department said that they “definitely” had enough time to discuss their condition …
OA02.03 The Third Generation EGFR Inhibitor (EGFR-TKI) HS-10296 in Advanced NSCLC Patients with Resistance to First Generation EGFR-TKI
Authors: S. Lu, Q. Wang, G. Zhang, X. Dong, C. Yang, Y. Song, G. Chang, Y. Lu, H. Pan, C. Chiu, Z. Wang, J. Feng, J. Zhou, X. Xu, R. Guo, J. Chen, H. Yang, Y. Chen, Z. Yu, H. Shiah, C. Wang, N. Yang, J. Fang, P. Wang, K. Wang, Y. Hu, J. He, Z. Wang, J. Shi, S. Chen, Y. Cheng, W. Su, T. Hsia, J. Cui, Y. Sun, C. Yang
Journal: Journal of Thoracic Oncology (2019)
EP1.01-55 Neoantigen Deletion Leads to Hyperprogressive Disease (HPD) in Non-Small Cell Lung Cancer (NSCLC) Treated with PD-1/PD-L1 Inhibitors
Authors: D. Wu, X. Hong, Y. Liu, K. Zhang, Y. Hu, F. Gu, Y. Liu, Z. Zhao, J. Liu, L. Liu
Journal: Journal of Thoracic Oncology (2019)
MA12.09 Checkpoint Inhibitors Synergize with Dendritic Cell-Therapy in Pre-Clinical Models and Mesothelioma Patients
Authors: R. Belderbos, F. Dammeijer, M. Gulijk, M. Lukkes, D. Dumoulin, R. Cornelissen, J. Aerts
Journal: Journal of Thoracic Oncology (2019)
P1.18-24 Neoadjuvant Therapy versus Upfront Surgery for NSCLC Patients with Clinically Suspected Subaortic or Paraaortic Lymph Nodes
Authors: J. Lee, S. Shin, J.H. Cho, H.K. Kim, Y.S. Choi, J.I. Zo, Y.M. Shim, J. Kim
Journal: Journal of Thoracic Oncology (2019)
Mapping genetic interactions in cancer: a road to rational combination therapies
Authors: Beril Tutuncuoglu, Nevan J. Krogan
Journal: Genome Medicine (2019)

Abstract The discovery of synthetic lethal interactions between poly (ADP-ribose) polymerase (PARP) inhibitors and BRCA genes, which are involved in homologous recombination, led to the approval of PARP inhibition as a monotherapy for patients with BRCA1/2 -mutated breast or ovarian cancer. Studies following the initial observation of synthetic lethality demonstrated that the reach of PARP inhibitors is well beyond just BRCA1/2 mutants. Insights into the mechanisms of action of anticancer drugs are fundamental for the development of targeted monotherapies or rational combination treatments that will synergize to promote cancer cell death and overcome mechanisms of resistance. The development of targeted therapeutic agents is premised on mapping the physical and functional dependencies of mutated genes in cancer. An important part of this effort is the systematic screening of genetic interactions in a variety of cancer types. Until recently, genetic-interaction screens have relied either on the pairwise perturbations of two genes or on the perturbation of genes of interest combined with inhibition by commonly used anticancer drugs. Here, we summarize recent advances in mapping genetic interactions using targeted, genome-wide, and high-throughput genetic screens, and we discuss the therapeutic insights obtained through such screens. We further focus on factors that should be considered in order to develop a robust analysis pipeline. Finally, we discuss the integration of functional interaction data with orthogonal methods and suggest that such approaches will increase the reach of genetic-interaction screens for the development of rational combination therapies.
Functional, Anatomical, and Prognostic Correlates of Coronary Flow Velocity Reserve During Stress Echocardiography
Authors: Quirino Ciampi, Angela Zagatina, Lauro Cortigiani, Nicola Gaibazzi, Clarissa Borguezan Daros, Nadezhda Zhuravskaya, Karina Wierzbowska-Drabik, Jaroslaw D. Kasprzak, José Luis de Castro e Silva Pretto, Antonello D'Andrea, Ana Djordjevic-Dikic, Ines Monte, Iana Simova, Alla Boshchenko, Rodolfo Citro, Miguel Amor, Pablo Martin Merlo, Claudio Dodi, Fausto Rigo, Suzana Gligorova, Milica Dekleva, Sergio Severino, Fabio Lattanzi, Maria Chiara Scali, Alexander Vrublevsky, Marco A.R. Torres, Alessandro Salustri, Hugo Rodrìguez-Zanella, Fabio Marco Costantino, Albert Varga, Eduardo Bossone, Paolo Colonna, Michele De Nes, Marco Paterni, Clara Carpeggiani, Jorge Lowenstein, Dario Gregori, Eugenio Picano
Journal: Journal of the American College of Cardiology (2019)
P1.04-50 Real World Efficacy of Pembrolizumab of as a 1st Line Treatment in Metastatic Non-Small Cell Lung Cancer with PD-L1 High Expression
Authors: K. Kasahara, T. Sone, K. Nishi, K. Shibata, T. Araya, H. Shirasaki, T. Yoneda, K. Kase, S. Nishikawa, H. Kimura, Y. Tambo
Journal: Journal of Thoracic Oncology (2019)
P2.14-58 A Phase IIIb, Open-Label Study of Afatinib in Caucasian EGFR TKI-Naïve Patients with EGFRm+ NSCLC: An Interim Analysis
Authors: F. De Marinis, K.K. Laktionov, A. Poltoratskiy, I. Egorova, M.J. Hochmair, A. Passaro, M.R. Migliorino, G. Metro, M. Gottfried, D. Tsoi, G. Ostoros, S. Rizzato, G.Z. Mukhametshina, M. Schumacher, S. Novello, R. Dziadziuszko, W. Tang, L. Clementi, A. Cseh, D. Kowalski
Journal: Journal of Thoracic Oncology (2019)
Engineering topography: Effects on corneal cell behavior and integration into corneal tissue engineering
Authors: Sijia Xiong, HuiChang Gao, Lanfeng Qin, Yong-Guang Jia, Li Ren
Journal: Bioactive Materials (2019)

Cell-material interactions are important to tissue engineering. Inspired by the natural topographic structures on the extracellular matrix, a growing number of studies have integrated engineering topography into investigations of cell behavior on biomaterials. Engineering topography has a significant influence on cell behaviors. These cell-topography interactions play an important role in regenerative medicine and tissue engineering. Similarly, cell-topography interactions are important to corneal reconstruction and regeneration. In this review, we primarily summarized the effects of topographic cues on the behaviors of corneal cells, including cell morphology, adhesion, migration, and proliferation. Furthermore, the integration of engineering surface topography into corneal tissue engineering was also discussed.
High-risk factors affecting survival after transcatheter therapy with doxorubicin-eluting beads for unresectable hepatocellular carcinoma
Authors: J. K. West, R. Dhanasekaran, D. A. Kooby, C. A. Staley, J. Kauh, H. S. Kim
Journal: Journal of Clinical Oncology (2009)

e15614 Background: Transcatheter therapy with drug eluting beads (DEB) with Doxorubicin is a relatively new modality of palliative treatment of patients with unresectable HCC. It is important to identify prognostic factors which affect survival after treatment with DEB to enable optimal patient selection and to ensure maximal survival benefit. Methods: Fifty consecutive patients with unresectable HCC who were treated with transcatheter therapy with DEB between the period of 2005 and 2008 were studied. Kaplan Meier test was used to study survival. Categorical variables were compared with Log rank test and continuous variable with Cox proportional hazards method. Results: The survival rates at one year from first transcatheter therapy in patients belonging to Okuda stage I, II and III were 67%, 35% and 27% (p=0.043). The survival rates at one year from the first transcatheter therapy in Child Pugh Class A, B and C were 60%, 39% and 13% (p=0.003). Portal vein thrombosis was present in 24%(12/50). Median survivals in patients with and without portal vein thrombosis were 335 days(31–638) and 610 days(482–738)(p=0.285). The median survival in patients with tumor thrombus and bland thrombus were 169 days and 335 days(p=0.69). The median survival in patients with main portal vein thrombosis and branch portal vein thromboses were 316 days(135–497) and 550 days(202–897)(p=0.89).Pre- procedure albumin, bilirubin and MELD score were found to be prognostic factors on univariate analysis ( Table 1 ).On multivariate analysis, pre-procedure serum albumin and Okuda staging were found to be independent prognostic factors. Conclusions: On multivariate analysis, serum albumin and Okuda staging were found to independently influence survival of patients treated with Doxorubicin eluting beads for unresectable hepatocellular carcinoma. The presence of portal vein thrombosis did not affect the long term survival. [Table: see text] No significant financial relationships to disclose.
P1.01-25 Real-World Outcomes of Advanced NSCLC Patients with Common and Uncommon/Complex EGFR Mutation Profiles
Authors: G. Riely, C. Lovly, C. Messina, S. Bienert, K. Alexander, W. Pao, K. Magee, S. Baxi, R. Doebele
Journal: Journal of Thoracic Oncology (2019)
MA25.03 Tumor-Infiltrating Lymphocytes (TIL) and Outcomes with Immunotherapy (ICI) or Chemotherapy in Advanced NSCLC (aNSCLC) Patients
Authors: L. Mezquita, I. Gataa, C. Rossoni, E. Auclin, M. Kossai, F. Aboubakar, S. Le Moulec, J. Massé, M. Masson, N. Radosevic-Robin, M. Rouanne, M. Bluthgen, C. Caramella, L. Hendriks, A. Gazzah, D. Planchard, J. Pignon, B. Besse, J. Adam
Journal: Journal of Thoracic Oncology (2019)
More Arrows in the Ancient DNA Quiver: Use of Paleoepigenomes and Paleomicrobiomes to Investigate Animal Adaptation to Environment
Authors: Yichen Liu, Laura S Weyrich, Bastien Llamas
Journal: Molecular Biology and Evolution (2019)

Whether and how epigenetic mechanisms and the microbiome play a role in mammalian adaptation raised considerable attention and controversy, mainly because they have the potential to add new insights into the Modern Synthesis. Recent attempts to reconcile neo-Darwinism and neo-Lamarckism in a unified theory of molecular evolution give epigenetic mechanisms and microbiome a prominent role. However, supporting empirical data are still largely missing. Because experimental studies using extant animals can hardly be done over evolutionary timescales, we propose that advances in ancient DNA techniques provide a valid alternative. In this piece, we evaluate 1) the possible roles of epigenomes and microbiomes in animal adaptation, 2) advances in the retrieval of paleoepigenome and paleomicrobiome data using ancient DNA techniques, and 3) the plasticity of either and interactions between the epigenome and the microbiome, while emphasizing that it is essential to take both into account, as well as the underlying genetic factors that may confound the findings. We propose that advanced ancient DNA techniques should be applied to a wide range of past animals, so novel dynamics in animal evolution and adaption can be revealed.
Isoniazid and Rifapentine Treatment Eradicates Persistent <i>Mycobacterium tuberculosis</i> in Macaques
Authors: Taylor W. Foreman, Allison N. Bucşan, Smriti Mehra, Charles Peloquin, Lara A. Doyle, Kasi Russell-Lodrigue, Neel R. Gandhi, John Altman, Cheryl L. Day, Joel D. Ernst, Henry M. Blumberg, Jyothi Rengarajan, Deepak Kaushal
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

Direct evidence for persistence of
MA21.11 A Multicenter Phase II Study of Low-Dose Erlotinib in Frail Patients with EGFR Mutation-Positive, Non-Small Cell Lung Cancer: TORG1425
Authors: S. Otani, K. Yamada, S. Miyamoto, K. Azuma, H. Ishii, A. Bessho, S. Hosokawa, H. Kunitoh, K. Miyazaki, H. Tanaka, S. Miura, H. Aono, Y. Nakahara, K. Kusaka, Y. Hosomi, A. Hamada, H. Okamoto
Journal: Journal of Thoracic Oncology (2019)
P1.04-25 CT Based Vessel Tortuosity Features Are Prognostic of Overall Survival and Predictive of Immunotherapy Response in NSCLC Patients
Authors: M. Alilou, P. Patil, P. Fu, K. Bera, V. Velcheti, A. Madabhushi, P. Vaidya
Journal: Journal of Thoracic Oncology (2019)
OA05.01 A Prospective Study of Swallowing and Voice Outcomes After Treatment for Small-Cell Lung Cancer
Authors: J. Frowen, K. Gough, J. Phipps-Nelson, R. Hughes, S. Siva, A. Drosdowsky, B. Solomon, N. Kiss, M. Duffy, D. Ball
Journal: Journal of Thoracic Oncology (2019)
EP1.04-01 Association of PD-L1 Expression with Lung Adenocarcinoma Containing Solid or Micropapillary Components
Authors: Y. Kidokoro, A. Nakanishi, S. Matsui, Y. Kubouchi, Y. Takagi, T. Haruki, Y. Taniguchi, Y. Umekita, H. Nakamura
Journal: Journal of Thoracic Oncology (2019)
Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia
Authors: Benshang Li, Samuel W. Brady, Xiaotu Ma, Shuhong Shen, Yingchi Zhang, Yongjin Li, Karol Szlachta, Li Dong, Yu Liu, Fan Yang, Ningling Wang, Diane A. Flasch, Matthew A. Myers, Heather L. Mulder, Lixia Ding, Yanling Liu, Liqing Tian, Kohei Hagiwara, Ke Xu, Xin Zhou, Edgar Sioson, Tianyi Wang, Liu Yang, Jie Zhao, Hui Zhang, Ying Shao, Hongye Sun, Lele Sun, Jiaoyang Cai, Hui-Ying Sun, Ting-Nien Lin, Lijuan Du, Hui Li, Michael Rusch, Michael N. Edmonson, John Easton, Xiaofan Zhu, Jingliao Zhang, Cheng Cheng, Benjamin J. Raphael, Jingyan Tang, James R. Downing, Ludmil B. Alexandrov, Bin-Bing S. Zhou, Ching-Hon Pui, Jun J. Yang, Jinghui Zhang
Journal: Blood (2019)